Standout Papers
Citation Impact
Citing Papers
Activation of Drosophila Toll During Fungal Infection by a Blood Serine Protease
2002 StandoutScienceNobel
De novo design of allosterically switchable protein assemblies
2024 StandoutNatureNobel
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
2001
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis
2000
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Endogenous human microRNAs that suppress breast cancer metastasis
2008 StandoutNature
Two Distinct Urokinase-Serpin Interactions Regulate the Initiation of Cell Surface-associated Plasminogen Activation
1999
Mechanism of activation of the TGF-β receptor
1994 StandoutNature
Ceramides in insulin resistance and lipotoxicity
2005
Structural aspects of serpin inhibition
1994 Nobel
Inflammation and cancer
2002 StandoutNature
Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas
2000
Importance of the P2 Glycine of Antithrombin in Target Proteinase Specificity, Heparin Activation, and the Efficiency of Proteinase Trapping as Revealed by a P2 Gly → Pro Mutation
1999
Receptors for the TGF-β superfamily: multiple polypeptides and serine/threonine kinases
1993
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
2007 StandoutNature
Plasminogen‐activator inhibitor type 2 (PAI‐2) is a spontaneously polymerising SERPIN
1993
Sp1 Sites Mediate Activation of the Plasminogen Activator Inhibitor-1 Promoter by Glucose in Vascular Smooth Muscle Cells
1998
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown
2018 StandoutNobel
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
1998
The Multiligand α2‐Macroglobulin Receptor/Low Density Lipoprotein Receptor‐Related Protein (α2MR/LRP)
1994
Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth
2004
Inhibition of Angiogenesis in Vivo by Plasminogen Activator Inhibitor-1
2001
TGF-β signaling in tumor suppression and cancer progression
2001 Standout
Intravital imaging of cell movement in tumours
2003
Preparation and Characterization of Latent α1-Antitrypsin
1995
The structural puzzle of how serpin serine proteinase inhibitors work
1996
Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1
1995
Antichymotrypsin Interaction with Chymotrypsin
1998
S‐ovalbumin, an ovalbumin conformer with properties analogous to those of loop‐inserted serpins
1995
The pH Dependence of Serpin-Proteinase Complex Dissociation Reveals a Mechanism of Complex Stabilization Involving Inactive and Active Conformational States of the Proteinase Which Are Perturbable by Calcium
2001
Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation
2000
Development and Disease in Proteinase-Deficient Mice
1998
The Low Density Lipoprotein Receptor-related Protein/α2-Macroglobulin Receptor Regulates Cell Surface Plasminogen Activator Activity on Human Trophoblast Cells
1998
Regulated portals of entry into the cell
2003 StandoutNature
Angiogenesis in cancer and other diseases
2000 StandoutNature
The Hallmarks of Cancer
2000 Standout
Topology of the Stable Serpin-Protease Complexes Revealed by an Autoantibody That Fails to React with the Monomeric Conformers of Antithrombin
1999
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling
2001
Phage-encoded combinatorial chemical libraries based on bicyclic peptides
2009 StandoutNobel
Engineering Plasminogen Activator Inhibitor 1 Mutants with Increased Functional Stability
1994
Cloning and characterization of hurpin (protease inhibitor 13): a new skin-specific, UV-repressible serine proteinase inhibitor of the ovalbumin serpin family
1999
Synergistic cooperation of TFE3 and Smad proteins in TGF-β-induced transcription of the plasminogen activator inhibitor-1 gene
1998
IκB: a Specific Inhibitor of the NF-κB Transcription Factor
1988 StandoutScienceNobel
Engineering Allosteric Regulation into Biological Catalysts
2009
Evidence That Translocation of the Proteinase Precedes Its Acylation in the Serpin Inhibition Pathway
2000
A Serpin Shapes the Extracellular Environment to Prevent Influenza A Virus Maturation
2015 StandoutNobel
Importance of the Hinge Region between α-Helix F and the Main Part of Serpins, Based upon Identification of the Epitope of Plasminogen Activator Inhibitor Type 1 Neutralizing Antibodies
2000
Unraveling hot spots in binding interfaces: progress and challenges
2002
Constraining Cyclic Peptides To Mimic Protein Structure Motifs
2014
The Serpin Inhibitory Mechanism Is Critically Dependent on the Length of the Reactive Center Loop
2001
Glial and neuronal control of brain blood flow
2010 StandoutNature
The microenvironment of the tumour–host interface
2001 StandoutNature
TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial–mesenchymal transition
2007
Crystal Structure of the Complex of Plasminogen Activator Inhibitor 2 with a Peptide Mimicking the Reactive Center Loop
2001
Partitioning of Serpin-Proteinase Reactions between Stable Inhibition and Substrate Cleavage Is Regulated by the Rate of Serpin Reactive Center Loop Insertion into β-Sheet A
2000
Role of Arginine 129 in Heparin Binding and Activation of Antithrombin
2000
Structural basis of latency in plasminogen activator inhibitor-1
1992 Nature
The structure of a Michaelis serpin-protease complex.
2001
Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues
1997
The structure of a serpin–protease complex revealed by intramolecular distance measurements using donor–donor energy migration and mapping of interaction sites
2000
Characterization of a Human α1-Antitrypsin Variant That Is as Stable as Ovalbumin
1998
Inactivation of Plasminogen Activator Inhibitor-1 by Specific Proteolysis with Stromelysin-1 (MMP-3)
2000
Biochemistry and molecular cell biology of diabetic complications
2001 StandoutNature
Urokinase- and Tissue-Type Plasminogen Activators in Keratinocytes During Wound Reepithelialization In Vivo
1988
Deep mutational scanning and massively parallel kinetics of plasminogen activator inhibitor-1 functional stability to probe its latency transition
2022
Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1
2001
Differential Stromal Regulation of MMP-1 Expression in Benign and Malignant Keratinocytes
2001
A matrix metalloproteinase expressed on the surface of invasive tumour cells
1994 StandoutNature
Matrix metalloproteinases in tumor invasion and metastasis
2000
ECM and Cell Surface Proteolysis: Regulating Cellular Ecology
1997
Regulation of the Ligand Binding Activity of the Human Very Low Density Lipoprotein Receptor by Protein Kinase C-dependent Phosphorylation
2001
SERPINB12 Is a Novel Member of the Human ov-serpin Family That Is Widely Expressed and Inhibits Trypsin-like Serine Proteinases
2001
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Plasminogen Activator Inhibitor-1 Contains a Cryptic High Affinity Binding Site for the Low Density Lipoprotein Receptor-related Protein
1998
Extracellular Matrix-Associated Transforming Growth Factor-β: Role in Cancer Cell Growth and Invasion
1998
Fibrinolysis, inflammation, and regulation of the plasminogen activating system
2007
The Very Low Density Lipoprotein Receptor Regulates Urokinase Receptor Catabolism and Breast Cancer Cell Motility in Vitro
1999
Breast cancer metastasis: markers and models
2005 Standout
Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes
1997
Coated pits, coated vesicles, and receptor-mediated endocytosis
1979 StandoutNatureNobel
Prediction of the structure of symmetrical protein assemblies
2007 StandoutNobel
Colocalization of DNA-binding and transcriptional activation functions in the human glucocorticoid receptor
1987
Glucocorticoid receptor mutants that are constitutive activators of transcriptional enhancement
1987 Nature
Quantitation of Transcription and Clonal Selection of Single Living Cells with β-Lactamase as Reporter
1998 StandoutScienceNobel
T-cell mitogens cause early changes in cytoplasmic free Ca2+ and membrane potential in lymphocytes
1982 StandoutNatureNobel
Bicyclic Peptide Inhibitor Reveals Large Contact Interface with a Protease Target
2012 StandoutNobel
Serpin Structure, Mechanism, and Function
2002 Standout
Primary structure and expression of a functional human glucocorticoid receptor cDNA
1985 StandoutNature
Functional rafts in cell membranes
1997 StandoutNature
Constitutive Activation of Toll-Mediated Antifungal Defense in Serpin-Deficient Drosophila
1999 StandoutScienceNobel
Functional domains of the human glucocorticoid receptor
1986
The Steroid and Thyroid Hormone Receptor Superfamily
1988 StandoutScience
Diversity of Allosteric Regulation in Proteases
2012
Inhibitory Serpins from Wheat Grain with Reactive Centers Resembling Glutamine-rich Repeats of Prolamin Storage Proteins
2000
The role of hormone receptors and GTP-regulatory proteins in membrane transduction
1980 StandoutNatureNobel
Proposed three-dimensional structure for the cellular prion protein.
1994 StandoutNobel
Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination
2002
Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression
2014 StandoutNobel
Uptake and degradation of 125I-labelled asialo-fetuin by isolated rat hepatocytes
1977
Clustered folate receptors deliver 5-methyltetrahydrofolate to cytoplasm of MA104 cells.
1996
Drug Discovery: A Historical Perspective
2000 StandoutScience
The serpin superfamily of proteinase inhibitors: structure, function, and regulation.
1994
Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells
1999
Wound Healing--Aiming for Perfect Skin Regeneration
1997 StandoutScience
Heterogeneity in Serpin−Protease Complexes As Demonstrated by Differences in the Mechanism of Complex Breakdown
2001
De novo design of covalently constrained mesosize protein scaffolds with unique tertiary structures
2017 StandoutNobel
A unique interhelical insertion in plasminogen activator inhibitor-2 contains three glutamines, Gln83, Gln84, Gln86, essential for transglutaminase-mediated cross-linking.
1994
Uptake and degdradation of formaldehyde-treated 125I-labeled human serum albumin in rat liver cells in vivo and in vitro
1977
Glycogen Synthase Kinase 3 Phosphorylates Hypoxia-Inducible Factor 1α and Mediates Its Destabilization in a VHL-Independent Manner
2007
Binding of urokinase-type plasminogen activator–plasminogen activator inhibitor-1 complex to the endocytosis receptors α2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor
1998
Is an early calcium flux necessary to stimulate lymphocytes?
1977 Nature
Functional domains of the very low density lipoprotein receptor: molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms
1999
Inhibition of Prostate-Specific Antigen (PSA) by α1-Antichymotrypsin: Salt-Dependent Activation Mediated by a Conformational Change
2002
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
2000
Characterization of the Calcium Site in Two Complement-like Domains from the Low-Density Lipoprotein Receptor-Related Protein (LRP) and Comparison with a Repeat from the Low-Density Lipoprotein Receptor
1998
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
Binding of 125I-labeled glucagon and glucagon-stimulated accumulation of adenosine 3‘:5‘-monophosphate in isolated intact rat hepatocytes. Evidence for receptor heterogeneity.
1978
Structures of Active and Latent PAI-1: A Possible Stabilizing Role for Chloride Ions
2000
Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily
1995 StandoutScience
Kinetically Controlled Folding of the Serpin Plasminogen Activator Inhibitor 1
1996
Matrix Metalloproteinases: A Review
1993 Standout
THE MAMMALIAN LOW-DENSITY LIPOPROTEIN RECEPTOR FAMILY
1999
Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
1992
Allosteric Modulation of Substrate Binding within a Tetracationic Molecular Receptor
2015 StandoutNobel
Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
1994
Stapled β-Hairpins Featuring 4-Mercaptoproline
2021 StandoutNobel
Functions of Cell Surface Heparan Sulfate Proteoglycans
1999 Standout
Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition
1979 StandoutNobel
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
2002
Photoaffinity labeling and partial proteolysis of wild-type and variant glucocorticoid receptors
1983
Active domains in wild-type and mutant glucocorticoid receptors.
1982
Accurate proteome-wide missense variant effect prediction with AlphaMissense
2023 StandoutScienceNobel
THE CAVEOLAE MEMBRANE SYSTEM
1998 Standout
Urokinase expression and binding activity associated with the transforming growth factor ?1-induced migratory and invasive phenotype of mouse epidermal keratinocytes
1999
A simple physical model for binding energy hot spots in protein–protein complexes
2002 StandoutNobel
Direct binding of Smad3 and Smad4 to critical TGFbeta -inducible elements in the promoter of human plasminogen activator inhibitor-type 1gene
1998 Standout
Works of Peter A. Andreasen being referenced
A Novel Mode of Intervention with Serine Protease Activity
2008
Antibody-induced Enhancement of Factor VIIa Activity through Distinct Allosteric Pathways
2012
Identification and characterization of urokinase receptors in natural killer cells and T‐cell‐derived lymphokine activated killer cells
1992
Crystal Structure of Plasminogen Activator Inhibitor-1 in an Active Conformation with Normal Thermodynamic Stability
2011
Receptor‐mediated endocytosis of plasminogen activators and activator/inhibitor complexes
1994
Urokinase binds to a plasminogen activator inhibitor type-2-like molecule in placental microvillous membranes
1989
Type‐1 Plasminogen‐Activator Inhibitor
1997
Localization of epitopes for monoclonal antibodies to urokinase‐type plasminogen activator
2001
Tumor necrosis factor-α regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines
1989
Conformational Changes of the Reactive‐Centre Loop and β‐Strand 5A Accompany Temperature‐Dependent Inhibitor‐Substrate Transition of Plasminogen‐Activator Inhibitor 1
1996
Breast Carcinoma Epithelial Cells Express a Very Low‐Density Lipoprotein Receptor Variant Lacking the O‐Linked Glycosylation Domain Encoded by Exon 16, But with Full Binding Activity for Serine Proteinase/Serpin Complexes and Mr‐40000 Receptor‐Associated Protein
1997
Plasminogen Activator Inhibitor-1 Represses Integrin- and Vitronectin-Mediated Cell Migration Independently of Its Function as an Inhibitor of Plasminogen Activation
1997
Additivity in Effects of Vitronectin and Monoclonal Antibodies against α-Helix F of Plasminogen Activator Inhibitor-1 on Its Reactions with Target Proteinases
2004
Importance of the amino‐acid composition of the shutter region of plasminogen activator inhibitor‐1 for its transitions to latent and substrate forms
2001
A Urokinase-type Plasminogen Activator-inhibiting Cyclic Peptide with an Unusual P2 Residue and an Extended Protease Binding Surface Demonstrates New Modalities for Enzyme Inhibition
2005
The Urokinase Receptor Is a Major Vitronectin-Binding Protein on Endothelial Cells
1996
Plasminogen activator inhibitors: hormonally regulated serpins
1990
Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor
1993
A common response element mediates differential effects of phorbol esters and forskolin on type‐1 plasminogen activator inhibitor gene expression in human breast carcinoma cells
1994
The urokinase-type plasminogen activator system in cancer metastasis: A review
1997 Standout
Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1
2007
Local Transient Unfolding of Native State PAI‐1 Associated with Serpin Metastability
2014
Engineering of conformations of plasminogen activator inhibitor‐1
1999
Very Low Density Lipoprotein Receptor Binds and Mediates Endocytosis of Urokinase-type Plasminogen Activator-Type-1 Plasminogen Activator Inhibitor Complex
1995
Type‐1 plasminogen activator inhibitor in human breast carcinomas
1992
Differential regulation of urokinase-type-1 inhibitor complex endocytosis by phorbol esters in different cell lines is associated with differential regulation of α2-macroglobulin receptor and urokinase receptor expression
1995
Bicyclic Peptide Inhibitor of Urokinase‐Type Plasminogen Activator: Mode of Action
2013
A serpin‐induced extensive proteolytic susceptibility of urokinase‐type plasminogen activator implicates distortion of the proteinase substrate‐binding pocket and oxyanion hole in the serpin inhibitory mechanism
2001
Type‐1 inhibitor of plasminogen activators
1991
Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type‐1
2001
Ligand Binding Properties of the Very Low Density Lipoprotein Receptor
1999
Protein Conformational Change Delayed by Steric Hindrance from an N-Linked Glycan
2013
Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and α2-macroglobulin receptor in human breast carcinomas
1996
Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis
2004
Specificity of Serine Proteinase/Serpin Complex Binding to Very‐Low‐Density Lipoprotein Receptor and α2‐Macroglobulin Receptor/Low‐Density‐Lipoprotein‐Receptor‐Related Protein
1997
Enzyme-Linked Immunosorbent Assay for Human Urokinase-Type Plasminogen Activator and its Proenzyme Using a Combination of Monoclonal and Polyclonal Antibodies
1986
Transforming Growth Factor βl-Responsive Element: Closely Associated Binding Sites for USF and CCAAT-Binding Transcription Factor-Nuclear Factor I in the Type 1 Plasminogen Activator Inhibitor Gene
1992
A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue
2008
Human endothelial cells contain one type of plasminogen activator
1984
Very low density lipoprotein receptor from mammary gland and mammary epithelial cell lines binds and mediates endocytosis of Mr, 40,000 receptor associated protein
1994
Plasminogen Activator Inhibitor type 1 Biosynthesis and mRNA Level are Increased by Dexamethasone in Human Fibrosarcoma Cells
1987
Analysis of a two-domain binding site for the urokinase-type plasminogen activator–plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein
2001
A rapid technique for separation of thymocytes from suspensions by centrifugation through silicone oil
1974
An Ester Bond Linking a Fragment of a Serine Proteinase to Its Serpin Inhibitor
1998
Dissecting the Effect of RNA Aptamer Binding on the Dynamics of Plasminogen Activator Inhibitor 1 Using Hydrogen/Deuterium Exchange Mass Spectrometry
2013
Latency transition of plasminogen activator inhibitor type 1 is evolutionarily conserved
2017
Activation and Partial Proteolysis of Variant Glucocorticoid Receptors, Studied by Two‐Phase Partitioning
1981
A Spectroscopic Study of the Structures of Latent, Active and Reactive‐Center‐Cleaved Type‐1 Plasminogen‐Activator Inhibitor
1996
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
1990
Hormonal regulation of extracellular plasminogen activators and Mr ∼ 54000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies
1986